{"transactions":[{"id":1384928,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":5287303,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":471415},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384927,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":11251624,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1003193},"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384926,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":763636,"price":11,"value":8399996.0,"ownership":{"direct":false,"nature":"By Northpond Ventures III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by Northpond Ventures III, LP (\"Northpond Fund III\").  Northpond Ventures III GP, LLC (\"Northpond III GP\") is the general partner of Northpond Fund III, and Michael P. Rubin is the managing member of Northpond III GP. As a result, each of Northpond III GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":763636,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384925,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":471415,"ownership":{"direct":false,"nature":"By Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Northpond Ventures, LP (\"Northpond Fund I\"). Northpond Ventures GP, LLC (\"Northpond GP I\") is the general partner of Northpond Fund I, and Michael P. Rubin is the managing member of Northpond GP I. As a result, each of Northpond GP I and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund I. Each of Northpond GP I and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":471415,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1384924,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":1,"cik":"0001869114","reported_name":"Northpond Ventures II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":2,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":3,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":4,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":5,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":6,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":7,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T18:34:47.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1003193,"ownership":{"direct":false,"nature":"By Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Northpond Ventures II, LP (\"Northpond Fund II\").  Northpond Ventures II GP, LLC (\"Northpond II GP\") is the general partner of Northpond Fund II, and Michael P. Rubin is the managing member of Northpond II GP. As a result, each of Northpond II GP and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond II GP and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1003193,"source":{"system":"sec-edgar","filing":"0001415889-24-025393","document":"form4-10172024_101042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000141588924025393/form4-10172024_101042.xml","form_type":"4"}},{"id":1845460,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T17:36:33.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":523503,"price":46.5,"value":24342889.5,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.44 to $46.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC. As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":166293,"source":{"system":"sec-edgar","filing":"0000899243-23-016413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924323016413/doc4.xml","form_type":"4"}},{"id":1845459,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T17:36:33.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":1969368,"price":46.5,"value":91575612.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $46.44 to $46.63, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC. As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":633707,"source":{"system":"sec-edgar","filing":"0000899243-23-016413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924323016413/doc4.xml","form_type":"4"}},{"id":2438028,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":1027978,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1027978},"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438027,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":2831520,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2831520},"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438026,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":355000,"price":14,"value":4970000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1382978,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438025,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":1027978,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":1027978,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2438024,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:18:29.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":2831520,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Vigil Neuroscience, Inc. (the \"Issuer\"), each share of Series A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Series B Preferred stock, par value $0.0001 per share of the Issuer (the \"Series B Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series B Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2831520,"source":{"system":"sec-edgar","filing":"0000899243-22-001631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924322001631/doc4.xml","form_type":"4"}},{"id":2564190,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":454796,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454796},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564189,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":867687,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":867687},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564188,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1735388,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1735388},"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564187,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":235000,"price":17,"value":3995000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":3292871,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564186,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":454796,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series C-1 Convertible Preferred Stock\"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":3057871,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2564185,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:19:52.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":2603075,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Series B Convertible Preferred Stock\"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the \"Series C Convertible Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2603075,"source":{"system":"sec-edgar","filing":"0000899243-21-036646","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321036646/doc4.xml","form_type":"4"}},{"id":2656170,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":4160529,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4160529},"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656169,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":5214851,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5241851},"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656168,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":468750,"price":16,"value":7500000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP II, LLC (\"Northpond GP II LLC\") is the general partner of Northpond Ventures II, LP (\"Northpond Fund II\"), and Michael P. Rubin is the managing member of Northpond GP II LLC.  As a result, each of Northpond GP II LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund II. Each of Northpond GP II LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":9844130,"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}},{"id":2656167,"issuer":{"id":15606,"kind":"organization","name":"Telesis Bio Inc.","symbol":"TBIO"},"owners":[{"id":86716,"kind":"organization","name":"Northpond Ventures GP, LLC","position":1,"cik":"0001867470","reported_name":"Northpond Ventures GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86717,"kind":"organization","name":"Northpond Ventures, LP","position":2,"cik":"0001867472","reported_name":"Northpond Ventures, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86714,"kind":"organization","name":"Northpond Ventures II GP, LLC","position":3,"cik":"0001869114","reported_name":"Northpond Ventures GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86715,"kind":"organization","name":"Northpond Ventures II, LP","position":4,"cik":"0001869128","reported_name":"Northpond Ventures II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":5,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-24T16:34:18.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":9375380,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of Codex DNA, Inc. (the \"Issuer\"), each share of Class A Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), of the Issuer and each share of Class A-1 Preferred stock, par value $0.0001 per share of the Issuer (the \"Series A-1 Preferred Stock\") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"). The right to convert the Series A Preferred Stock and Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures GP, LLC (\"Northpond GP LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond GP LLC.  As a result, each of Northpond GP LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Each of Northpond GP LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":9375380,"source":{"system":"sec-edgar","filing":"0000899243-21-025745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869114/000089924321025745/doc4.xml","form_type":"4"}}]}